Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | RAD52 | P43351 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 4/20 | 0.38 |
| ▸ | HTR2C | P28335 | 4/20 | 0.38 |
| ▸ | GCK | P35557 | 2/20 | 0.38 |
| ▸ | TRPC6 | Q9Y210 | 2/20 | 0.37 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1722334 | 0.86 | GCK (0.39) | TMEM97SIGMAR1MAPTKDM4ERAD52 | |
| SCHEMBL30664067 | 0.81 | GAA (0.62) | MAPTKDM4ERAD52GAAGFER | |
| SCHEMBL611882 | 0.81 | GAA (0.62) | MAPTKDM4ERAD52GAAGFER | |
| SCHEMBL6550226 | 0.80 | MAPT (0.61) | TMEM97SIGMAR1MAPTCYP1A2CYP3A4 | |
| SCHEMBL19966551 | 0.79 | CYP2D6 (0.45) | SIGMAR1MAPTCYP2D6KDM4ERAD52 | |
| SCHEMBL1393706 | 0.78 | CYP2D6 (0.41) | MAPTCYP2D6KDM4ERAD52GAA | |
| SCHEMBL20332608 | 0.78 | ROCK2 (0.46) | MAPTCYP3A4CYP2C9CYP2C19KDM4E | |
| SCHEMBL17108487 | 0.78 | DRD2 (0.54) | SIGMAR1MAPTKDM4ERAD52GAA | |
| SCHEMBL27977065 | 0.78 | GCK (0.38) | MAPTCYP2D6KDM4ERAD52GAA | |
| SCHEMBL29437380 | 0.77 | PIK3CA (0.42) | MAPTKDM4ERAD52GAAGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476275-B2 | N-[piperazinyl hetaryl]arylsufonamide compounds with affinity for the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-07-02 | — | — | US | disclosed |
| US-20110294817-A1 | N-[PIPERAZINYL HETARYL]ARYLSUFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2011-12-01 | — | — | US | disclosed |
| EP-1613596-B1 | N-[(PIPERAZINYL)HETARYL]ARYLSULFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2008-03-12 | — | — | EP | disclosed |
| US-7320979-B2 | N-[(piperazinyl)hetaryl]arylsulfonamide compounds | ABBOTT GMBH & CO. KG. (DE) | 2008-01-22 | — | — | US | disclosed |
| US-20070054918-A1 | N-[(piperazinyl)hetary]arylsulfonamide compounds with affinity for the dopamine d3 receptor | ABBOTT GMBH & CO. KG (DE) | 2007-03-08 | — | — | US | disclosed |
| US-20060160809-A1 | N-[(piperazinyl)hetaryl]arylsulfonamide compounds | ABBOTT GMBH & CO. KG. | 2006-07-20 | — | — | US | disclosed |
| EP-1613596-A1 | N-[(PIPERAZINYL)HETARYL]ARYLSULFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004089905-A1 | N-[(PIPERAZINYL)HETARYL]ARYLSULFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204422-A1 | N-[(Piperazinyl)hetaryl]arylsulfonamide compounds | ABBOTT GMBH & CO. KG. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204422-A1 | N-[(Piperazinyl)hetaryl]arylsulfonamide compounds | CBR1, CBR3, CNR2 | TMEM97 1051/4885SIGMAR1 167/4885MAPT 4659/4885 |
| US-20110294817-A1 | N-[PIPERAZINYL HETARYL]ARYLSUFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR | DRD2, DRD3, TACR1 | TMEM97 846/4885SIGMAR1 136/4885MAPT 4633/4885 |
| US-20070054918-A1 | N-[(piperazinyl)hetary]arylsulfonamide compounds with affinity for the dopamine d3 receptor | PTGDR, TACR1, TACR2 | TMEM97 1016/4885SIGMAR1 123/4885MAPT 4631/4885 |
| US-20060160809-A1 | N-[(piperazinyl)hetaryl]arylsulfonamide compounds | CBR3, CNR2, CNR1 | TMEM97 1382/4885SIGMAR1 122/4885MAPT 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.